2.9M XNAS Volume
XNAS 18 Mar, 2025 5:30 PM (EDT)
| Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|
| Christine Chung | SVP, CHINA OPERATIONS | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.39 per share. | 06 Mar 2025 | 7,008 | 294,544 (0%) | 0% | 0.4 | 2,733 | Common Stock |
| Christine Chung | SVP, CHINA OPERATIONS | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Mar 2025 | 781 | 295,325 (0%) | 0% | 0 | Common Stock | |
| Christine Chung | SVP, CHINA OPERATIONS | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.39 per share. | 06 Mar 2025 | 422 | 294,903 (0%) | 0% | 0.4 | 165 | Common Stock |
| Thane Wettig | Director, CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.39 per share. | 06 Mar 2025 | 367 | 398,329 (0%) | 0% | 0.4 | 143 | Common Stock |
| Thane Wettig | Director, CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.39 per share. | 06 Mar 2025 | 22,038 | 397,915 (0%) | 0% | 0.4 | 8,595 | Common Stock |
| Thane Wettig | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Mar 2025 | 781 | 398,696 (0%) | 0% | 0 | Common Stock | |
| David DeLucia | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.39 per share. | 06 Mar 2025 | 2,325 | 116,137 (0%) | 0% | 0.4 | 907 | Common Stock |
| Christine Chung | SVP, CHINA OPERATIONS | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.34 per share. | 06 Dec 2024 | 2,792 | 301,552 (0%) | 0% | 0.3 | 955 | Common Stock |
| Thane Wettig | Director, CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.34 per share. | 06 Dec 2024 | 2,363 | 419,953 (0%) | 0% | 0.3 | 808 | Common Stock |
| Juan Graham | CHIEF FINANCIAL OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.34 per share. | 06 Dec 2024 | 1,066 | 164,863 (0%) | 0% | 0.3 | 365 | Common Stock |
| Juan Graham | CHIEF FINANCIAL OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.34 per share. | 06 Dec 2024 | 1,446 | 165,929 (0%) | 0% | 0.3 | 495 | Common Stock |
| Christine Chung | SVP, CHINA OPERATIONS | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.39 per share. | 06 Sep 2024 | 17,395 | 304,344 (0%) | 0% | 0.4 | 6,784 | Common Stock |
| Thane Wettig | Director, CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.39 per share. | 06 Sep 2024 | 2,363 | 422,316 (0%) | 0% | 0.4 | 922 | Common Stock |
| Juan Graham | CHIEF FINANCIAL OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.39 per share. | 06 Sep 2024 | 1,065 | 167,375 (0%) | 0% | 0.4 | 415 | Common Stock |
| Juan Graham | CHIEF FINANCIAL OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.39 per share. | 06 Sep 2024 | 16,050 | 168,440 (0%) | 0% | 0.4 | 6,260 | Common Stock |
| Thane Wettig | Director, CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.47 per share. | 01 Aug 2024 | 20,840 | 424,679 (0%) | 0% | 0.5 | 9,795 | Common Stock |
| Thane Wettig | Director, CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.13 per share. | 22 Jun 2024 | 782 | 445,519 (0%) | 0% | 1.1 | 884 | Common Stock |
| Deyaa Adib | Chief Medical Officer | Purchase of securities on an exchange or from another person at price $ 1.17 per share. | 12 Jun 2024 | 22,123 | 82,123 (0%) | 0% | 1.2 | 25,884 | Common Stock |
| Christine Chung | SVP, CHINA OPERATIONS | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.19 per share. | 06 Jun 2024 | 19,289 | 321,739 (0%) | 0% | 1.2 | 22,954 | Common Stock |
| Thane Wettig | Director, CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.19 per share. | 06 Jun 2024 | 2,255 | 446,301 (0%) | 0% | 1.2 | 2,683 | Common Stock |
| Juan Graham | CHIEF FINANCIAL OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.10 per share. | 06 Jun 2024 | 1,182 | 184,490 (0%) | 0% | 1.1 | 1,300 | Common Stock |
| Juan Graham | CHIEF FINANCIAL OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.19 per share. | 06 Jun 2024 | 17,797 | 185,672 (0%) | 0% | 1.2 | 21,178 | Common Stock |
| James A. Schoeneck | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2024 | 70,000 | 70,000 | - | - | Stock Option (Right to Buy) | |
| Jeffrey L. Edwards | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2024 | 70,000 | 70,000 | - | - | Stock Option (Right to Buy) | |
| Maykin Ho | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2024 | 70,000 | 70,000 | - | - | Stock Option (Right to Buy) | |
| Aoife M. Brennan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2024 | 70,000 | 70,000 | - | - | Stock Option (Right to Buy) | |
| Gerald Lema | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2024 | 70,000 | 70,000 | - | - | Stock Option (Right to Buy) | |
| Suzanne Blaug | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2024 | 70,000 | 70,000 | - | - | Stock Option (Right to Buy) | |
| Benjamin F. Cravatt | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2024 | 70,000 | 70,000 | - | - | Stock Option (Right to Buy) | |
| Thane Wettig | Director, CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.17 per share. | 01 May 2024 | 20,840 | 448,556 (0%) | 0% | 1.2 | 24,383 | Common Stock |
| Thane Wettig | Director, CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.58 per share. | 22 Mar 2024 | 782 | 469,396 (0%) | 0% | 2.6 | 2,018 | Common Stock |
| Thane Wettig | CEO | Purchase of securities on an exchange or from another person at price $ 1.91 per share. | 07 Mar 2024 | 50,000 | 470,178 (0%) | 0% | 1.9 | 95,470 | Common Stock |
| Christine Chung | SVP, CHINA OPERATIONS | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.87 per share. | 06 Mar 2024 | 23,168 | 340,669 (0%) | 0% | 1.9 | 43,324 | Common Stock |
| Christine Chung | SVP, CHINA OPERATIONS | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.87 per share. | 06 Mar 2024 | 422 | 341,028 (0%) | 0% | 1.9 | 789 | Common Stock |
| Christine Chung | SVP, CHINA OPERATIONS | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Mar 2024 | 781 | 341,450 (0%) | 0% | 0 | Common Stock | |
| Thane Wettig | CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.87 per share. | 06 Mar 2024 | 4,209 | 419,723 (0%) | 0% | 1.9 | 7,871 | Common Stock |
| Thane Wettig | CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.87 per share. | 06 Mar 2024 | 326 | 420,178 (0%) | 0% | 1.9 | 610 | Common Stock |
| Thane Wettig | CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Mar 2024 | 781 | 420,504 (0%) | 0% | 0 | Common Stock | |
| Juan Graham | CHIEF FINANCIAL OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.79 per share. | 06 Mar 2024 | 1,181 | 203,469 (0%) | 0% | 1.8 | 2,114 | Common Stock |
| Juan Graham | CHIEF FINANCIAL OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.87 per share. | 06 Mar 2024 | 20,327 | 204,291 (0%) | 0% | 1.9 | 38,011 | Common Stock |
| Juan Graham | CHIEF FINANCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Mar 2024 | 781 | 205,072 (0%) | 0% | 0 | Common Stock | |
| Juan Graham | CHIEF FINANCIAL OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.87 per share. | 06 Mar 2024 | 422 | 204,650 (0%) | 0% | 1.9 | 789 | Common Stock |
| Wettig Thane | CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Feb 2024 | 834,000 | 834,000 | - | - | Stock Option (Right to Buy) | |
| Graham Juan | CHIEF FINANCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Feb 2024 | 52,000 | 224,618 (0%) | 0% | 0 | Common Stock | |
| Chung Christine | SVP, CHINA OPERATIONS | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Feb 2024 | 29,000 | 363,837 (0%) | 0% | 0 | Common Stock | |
| Thane Wettig | CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Feb 2024 | 166,000 | 423,932 (0%) | 0% | 0 | Common Stock | |
| Christine Chung | SVP, CHINA OPERATIONS | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Feb 2024 | 143,000 | 143,000 | - | - | Stock Option (Right to Buy) | |
| Graham Juan | CHIEF FINANCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Feb 2024 | 260,000 | 260,000 | - | - | Stock Option (Right to Buy) | |
| Wettig Thane | CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.37 per share. | 01 Feb 2024 | 23,490 | 257,932 (0%) | 0% | 2.4 | 55,671 | Common Stock |
| Wettig Thane | CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.76 per share. | 22 Dec 2023 | 819 | 281,422 (0%) | 0% | 0.8 | 622 | Common Stock |
| Graham Juan | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.58 per share. | 06 Dec 2023 | 15,573 | 173,703 (0%) | 0% | 0.6 | 9,032 | Common Stock |
| Graham Juan | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.62 per share. | 06 Dec 2023 | 1,085 | 172,618 (0%) | 0% | 0.6 | 668 | Common Stock |
| Christine Chung | SVP, China Operations | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.58 per share. | 06 Dec 2023 | 18,182 | 334,837 (0%) | 0% | 0.6 | 10,546 | Common Stock |
| Thane Wettig | CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.58 per share. | 06 Dec 2023 | 1,680 | 282,241 (0%) | 0% | 0.6 | 974 | Common Stock |
| James A. Schoeneck | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Aug 2023 | 10,000 | 10,000 | - | - | Stock Option (Right to Buy) | |
| Thane Wettig | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Aug 2023 | 300,000 | 300,000 | - | - | Stock Option (Right to Buy) | |
| Thane Wettig | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Aug 2023 | 200,000 | 308,261 (0%) | 0% | 0 | Common Stock | |
| Jeffrey W. Henderson | Director | Sale of securities on an exchange or to another person at price $ 1.91 per share. | 04 Aug 2023 | 2,000 | 30,866 (0%) | 0% | 1.9 | 3,820 | Common Stock |
| Jeffrey W. Henderson | Director | Sale of securities on an exchange or to another person at price $ 2.69 per share. | 11 Jul 2023 | 2,000 | 32,866 (0%) | 0% | 2.7 | 5,380 | Common Stock |
| Enrique A. Conterno | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 2.80 per share. | 07 Jul 2023 | 1,880 | 374,722 (0%) | 0% | 2.8 | 5,264 | Common Stock |
| Thane Wettig | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 16.53 per share. | 23 Jun 2023 | 791 | 108,261 (0%) | 0% | 16.5 | 13,075 | Common Stock |
| Christine Chung | SVP, China Operations | Sale of securities on an exchange or to another person at price $ 17.46 per share. | 13 Jun 2023 | 1,000 | 236,327 (0%) | 0% | 17.5 | 17,460 | Common Stock |
| Christine Chung | SVP, China Operations | Sale of securities on an exchange or to another person at price $ 17.60 per share. | 13 Jun 2023 | 6,250 | 242,577 (0%) | 0% | 17.6 | 110,000 | Common Stock |
| Christine Chung | SVP, China Operations | Sale of securities on an exchange or to another person at price $ 16.66 per share. | 13 Jun 2023 | 5,250 | 237,327 (0%) | 0% | 16.7 | 87,465 | Common Stock |
| James A. Schoeneck | Director | Sale of securities on an exchange or to another person at price $ 18.03 per share. | 07 Jun 2023 | 7,100 | 73,722 (0%) | 0% | 18.0 | 127,987 | Common Stock |
| James A. Schoeneck | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2023 | 8,289 | 28,766 (0%) | 0% | 0 | Common Stock | |
| James A. Schoeneck | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2023 | 12,666 | 12,666 | - | - | Stock Option (Right to Buy) | |
| Jeffrey L. Edwards | Director | Sale of securities on an exchange or to another person at price $ 16.74 per share. | 07 Jun 2023 | 3,265 | 38,601 (0%) | 0% | 16.7 | 54,656 | Common Stock |
| Jeffrey L. Edwards | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2023 | 12,666 | 12,666 | - | - | Stock Option (Right to Buy) | |
| Jeffrey L. Edwards | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2023 | 8,289 | 41,866 (0%) | 0% | 0 | Common Stock | |
| Jeffrey L. Edwards | Director | Sale of securities on an exchange or to another person at price $ 17.51 per share. | 07 Jun 2023 | 4,624 | 33,977 (0%) | 0% | 17.5 | 80,966 | Common Stock |
| Jeffrey W. Henderson | Director | Sale of securities on an exchange or to another person at price $ 17.69 per share. | 07 Jun 2023 | 4,994 | 34,866 (0%) | 0% | 17.7 | 88,344 | Common Stock |
| Jeffrey W. Henderson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2023 | 12,666 | 12,666 | - | - | Stock Option (Right to Buy) | |
| Jeffrey W. Henderson | Director | Sale of securities on an exchange or to another person at price $ 16.87 per share. | 07 Jun 2023 | 2,006 | 39,860 (0%) | 0% | 16.9 | 33,841 | Common Stock |
| Jeffrey W. Henderson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2023 | 8,289 | 41,866 (0%) | 0% | 0 | Common Stock | |
| Enrique A. Conterno | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 17.04 per share. | 07 Jun 2023 | 2,791 | 382,708 (0%) | 0% | 17.0 | 47,550 | Common Stock |
| Enrique A. Conterno | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 17.04 per share. | 07 Jun 2023 | 6,106 | 376,602 (0%) | 0% | 17.0 | 104,033 | Common Stock |
| Maykin Ho | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2023 | 12,666 | 12,666 | - | - | Stock Option (Right to Buy) | |
| Maykin Ho | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2023 | 8,289 | 40,021 (0%) | 0% | 0 | Common Stock | |
| Maykin Ho | Director | Sale of securities on an exchange or to another person at price $ 16.79 per share. | 07 Jun 2023 | 2,295 | 37,726 (0%) | 0% | 16.8 | 38,533 | Common Stock |
| Maykin Ho | Director | Sale of securities on an exchange or to another person at price $ 17.68 per share. | 07 Jun 2023 | 6,225 | 31,501 (0%) | 0% | 17.7 | 110,058 | Common Stock |
| Aoife M. Brennan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2023 | 12,666 | 12,666 | - | - | Stock Option (Right to Buy) | |
| Aoife M. Brennan | Director | Sale of securities on an exchange or to another person at price $ 16.74 per share. | 07 Jun 2023 | 1,994 | 30,686 (0%) | 0% | 16.7 | 33,380 | Common Stock |
| Aoife M. Brennan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2023 | 8,289 | 32,680 (0%) | 0% | 0 | Common Stock | |
| Aoife M. Brennan | Director | Sale of securities on an exchange or to another person at price $ 17.52 per share. | 07 Jun 2023 | 2,739 | 27,947 (0%) | 0% | 17.5 | 47,987 | Common Stock |
| Gerald Lema | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2023 | 12,666 | 12,666 | - | - | Stock Option (Right to Buy) | |
| Gerald Lema | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2023 | 8,289 | 28,766 (0%) | 0% | 0 | Common Stock | |
| Christine Chung | SVP, China Operations | Sale of securities on an exchange or to another person at price $ 17.04 per share. | 07 Jun 2023 | 1,532 | 248,827 (0%) | 0% | 17.0 | 26,102 | Common Stock |
| Christine Chung | SVP, China Operations | Sale of securities on an exchange or to another person at price $ 17.04 per share. | 07 Jun 2023 | 1,362 | 251,098 (0%) | 0% | 17.0 | 23,202 | Common Stock |
| Christine Chung | SVP, China Operations | Sale of securities on an exchange or to another person at price $ 17.04 per share. | 07 Jun 2023 | 739 | 250,359 (0%) | 0% | 17.0 | 12,590 | Common Stock |
| Suzanne Blaug | Director | Sale of securities on an exchange or to another person at price $ 16.73 per share. | 07 Jun 2023 | 3,351 | 34,763 (0%) | 0% | 16.7 | 56,062 | Common Stock |
| Suzanne Blaug | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2023 | 12,666 | 12,666 | - | - | Stock Option (Right to Buy) | |
| Suzanne Blaug | Director | Sale of securities on an exchange or to another person at price $ 17.51 per share. | 07 Jun 2023 | 5,169 | 29,594 (0%) | 0% | 17.5 | 90,509 | Common Stock |
| Suzanne Blaug | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2023 | 8,289 | 38,114 (0%) | 0% | 0 | Common Stock | |
| Thane Wettig | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 17.04 per share. | 07 Jun 2023 | 472 | 110,338 (0%) | 0% | 17.0 | 8,041 | Common Stock |
| Thane Wettig | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 17.04 per share. | 07 Jun 2023 | 1,286 | 109,052 (0%) | 0% | 17.0 | 21,910 | Common Stock |
| Benjamin Cravatt | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2023 | 12,666 | 12,666 | - | - | Stock Option (Right to Buy) | |
| Benjamin Cravatt | Director | Sale of securities on an exchange or to another person at price $ 16.75 per share. | 07 Jun 2023 | 1,766 | 30,914 (0%) | 0% | 16.8 | 29,581 | Common Stock |
| Benjamin Cravatt | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2023 | 8,289 | 32,680 (0%) | 0% | 0 | Common Stock | |
| Benjamin Cravatt | Director | Sale of securities on an exchange or to another person at price $ 17.51 per share. | 07 Jun 2023 | 2,178 | 28,736 (0%) | 0% | 17.5 | 38,137 | Common Stock |
| Mark Eisner | EVP, Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 17.04 per share. | 07 Jun 2023 | 2,042 | 162,862 (0%) | 0% | 17.0 | 34,792 | Common Stock |
| Juan Graham | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 16.95 per share. | 07 Jun 2023 | 1,050 | 71,818 (0%) | 0% | 16.9 | 17,797 | Common Stock |
| Juan Graham | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 17.04 per share. | 07 Jun 2023 | 735 | 71,083 (0%) | 0% | 17.0 | 12,523 | Common Stock |
| Mark Eisner | EVP, Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 18.83 per share. | 02 Jun 2023 | 1,090 | 164,904 (0%) | 0% | 18.8 | 20,525 | Common Stock |
| Enrique A. Conterno | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 19.52 per share. | 10 Apr 2023 | 1,869 | 382,999 (0%) | 0% | 19.5 | 36,483 | Common Stock |
| Christine Chung | SVP, China Operations | Sale of securities on an exchange or to another person at price $ 18.78 per share. | 04 Apr 2023 | 6,590 | 252,460 (0%) | 0% | 18.8 | 123,785 | Common Stock |
| Mark Eisner | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 18.78 per share. | 04 Apr 2023 | 9,182 | 165,994 (0%) | 0% | 18.8 | 172,473 | Common Stock |
| Thane Wettig | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 18.71 per share. | 23 Mar 2023 | 905 | 110,653 (0%) | 0% | 18.7 | 16,933 | Common Stock |
| Thane Wettig | Chief Commercial Officer | Gift of securities by or to the insider at price $ 0.00 per share. | 20 Mar 2023 | 2,343 | 108,310 (0%) | 0% | 0 | Common Stock | |
| Thane Wettig | Chief Commercial Officer | Gift of securities by or to the insider at price $ 0.00 per share. | 20 Mar 2023 | 1,000 | 1,000 (0%) | 0% | 0 | Common Stock | |
| Enrique A. Conterno | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 20.20 per share. | 08 Mar 2023 | 19,489 | 384,868 (0%) | 0% | 20.2 | 393,625 | Common Stock |
| Christine Chung | SVP, China Operations | Sale of securities on an exchange or to another person at price $ 20.20 per share. | 08 Mar 2023 | 4,692 | 261,964 (0%) | 0% | 20.2 | 94,766 | Common Stock |
| Christine Chung | SVP, China Operations | Sale of securities on an exchange or to another person at price $ 21.16 per share. | 08 Mar 2023 | 8,354 | 251,519 (0%) | 0% | 21.2 | 176,736 | Common Stock |
| Christine Chung | SVP, China Operations | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Mar 2023 | 5,799 | 257,318 (0%) | 0% | 0 | Common Stock | |
| Christine Chung | SVP, China Operations | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Mar 2023 | 9,338 | 266,656 (0%) | 0% | 0 | Common Stock | |
| Christine Chung | SVP, China Operations | Sale of securities on an exchange or to another person at price $ 20.20 per share. | 08 Mar 2023 | 2,914 | 259,050 (0%) | 0% | 20.2 | 58,855 | Common Stock |
| Thane Wettig | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Mar 2023 | 5,799 | 109,889 (0%) | 0% | 0 | Common Stock | |
| Thane Wettig | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 21.16 per share. | 08 Mar 2023 | 6,265 | 104,090 (0%) | 0% | 21.2 | 132,542 | Common Stock |
| Thane Wettig | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 20.20 per share. | 08 Mar 2023 | 4,731 | 111,558 (0%) | 0% | 20.2 | 95,553 | Common Stock |
| Thane Wettig | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 20.20 per share. | 08 Mar 2023 | 2,938 | 116,289 (0%) | 0% | 20.2 | 59,340 | Common Stock |
| Thane Wettig | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Mar 2023 | 9,338 | 119,227 (0%) | 0% | 0 | Common Stock | |
| Mark Eisner | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Mar 2023 | 7,732 | 172,865 (0%) | 0% | 0 | Common Stock | |
| Mark Eisner | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 21.16 per share. | 08 Mar 2023 | 7,363 | 165,133 (0%) | 0% | 21.2 | 155,771 | Common Stock |
| Mark Eisner | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 20.20 per share. | 08 Mar 2023 | 6,255 | 175,176 (0%) | 0% | 20.2 | 126,334 | Common Stock |
| Mark Eisner | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 20.20 per share. | 08 Mar 2023 | 3,885 | 181,431 (0%) | 0% | 20.2 | 78,467 | Common Stock |
| Mark Eisner | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Mar 2023 | 12,451 | 185,316 (0%) | 0% | 0 | Common Stock | |
| Juan Graham | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 20.20 per share. | 08 Mar 2023 | 1,112 | 76,668 (0%) | 0% | 20.2 | 22,459 | Common Stock |
| Juan Graham | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 20.20 per share. | 08 Mar 2023 | 2,344 | 72,868 (0%) | 0% | 20.2 | 47,342 | Common Stock |
| Juan Graham | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 20.20 per share. | 08 Mar 2023 | 1,456 | 75,212 (0%) | 0% | 20.2 | 29,407 | Common Stock |
| Juan Graham | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Mar 2023 | 4,668 | 77,780 (0%) | 0% | 0 | Common Stock | |
| Juan Graham | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Mar 2023 | 2,899 | 73,112 (0%) | 0% | 0 | Common Stock | |
| Juan Graham | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 21.16 per share. | 08 Mar 2023 | 2,749 | 70,213 (0%) | 0% | 21.2 | 58,158 | Common Stock |
| Mark Eisner | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 21.87 per share. | 02 Mar 2023 | 1,187 | 172,496 (0%) | 0% | 21.9 | 25,960 | Common Stock |
| Enrique A. Conterno | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Feb 2023 | 143,100 | 143,100 | - | - | Stock Option (Right to Buy) | |
| Enrique A. Conterno | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Feb 2023 | 85,300 | 380,783 (0%) | 0% | 0 | Common Stock | |
| Christine Chung | SVP, China Operations | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Feb 2023 | 42,000 | 42,000 | - | - | Stock Option (Right to Buy) | |
| Christine Chung | SVP, China Operations | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Feb 2023 | 25,000 | 259,873 (0%) | 0% | 0 | Common Stock | |
| Thane Wettig | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Feb 2023 | 42,000 | 42,000 | - | - | Stock Option (Right to Buy) | |
| Thane Wettig | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Feb 2023 | 25,000 | 110,355 (0%) | 0% | 0 | Common Stock | |
| Mark Eisner | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Feb 2023 | 55,000 | 55,000 | - | - | Stock Option (Right to Buy) | |
| Mark Eisner | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Feb 2023 | 32,500 | 173,683 (0%) | 0% | 0 | Common Stock | |
| Juan Graham | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Feb 2023 | 42,000 | 42,000 | - | - | Stock Option (Right to Buy) | |
| Juan Graham | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Feb 2023 | 25,000 | 72,962 (0%) | 0% | 0 | Common Stock | |
| Enrique A. Conterno | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 19.95 per share. | 06 Jan 2023 | 1,538 | 295,483 (0%) | 0% | 19.9 | 30,683 | Common Stock |
| Thane Wettig | Chief Commercial Officer | Gift of securities by or to the insider at price $ 0.00 per share. | 31 Dec 2022 | 1,988 | 87,175 (0%) | 0% | 0 | Common Stock | |
| Thane Wettig | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 15.80 per share. | 23 Dec 2022 | 734 | 89,163 (0%) | 0% | 15.8 | 11,597 | Common Stock |
| Juan Graham | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 14.50 per share. | 09 Dec 2022 | 1,407 | 47,962 (0%) | 0% | 14.5 | 20,402 | Common Stock |
| Juan Graham | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 14.89 per share. | 09 Dec 2022 | 781 | 49,369 (0%) | 0% | 14.9 | 11,629 | Common Stock |
| Christine Chung | SVP, China Operations | Sale of securities on an exchange or to another person at price $ 15.79 per share. | 08 Dec 2022 | 2,595 | 234,873 (0%) | 0% | 15.8 | 40,975 | Common Stock |
| Juan Graham | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 14.84 per share. | 08 Dec 2022 | 5,263 | 50,628 (0%) | 0% | 14.8 | 78,103 | Common Stock |
| Juan Graham | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 15.47 per share. | 08 Dec 2022 | 478 | 50,150 (0%) | 0% | 15.5 | 7,395 | Common Stock |
| Mark Eisner | Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 15.04 per share. | 01 Dec 2022 | 1,084 | 141,183 (0%) | 0% | 15.0 | 16,303 | Common Stock |
| Enrique A. Conterno | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 14.26 per share. | 06 Oct 2022 | 1,296 | 299,563 (0%) | 0% | 14.3 | 18,481 | Common Stock |
| Christine Chung | SVP, China Operations | Payment of exercise price or tax liability using portion of securities received from the company at price $ 13.01 per share. | 30 Sep 2022 | 4,683 | 238,801 (0%) | 0% | 13.0 | 60,926 | Common Stock |
| Mark Eisner | Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 13.01 per share. | 30 Sep 2022 | 6,777 | 142,267 (0%) | 0% | 13.0 | 88,169 | Common Stock |
| Thane Wettig | Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 12.26 per share. | 22 Sep 2022 | 655 | 90,279 (0%) | 0% | 12.3 | 8,030 | Common Stock |
| Juan Graham | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 12.62 per share. | 07 Sep 2022 | 3,009 | 55,891 (0%) | 0% | 12.6 | 37,974 | Common Stock |
| Enrique A. Conterno | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 12.26 per share. | 06 Sep 2022 | 1,772 | 300,859 (0%) | 0% | 12.3 | 21,725 | Common Stock |
| Christine Chung | SVP, China Operations | Payment of exercise price or tax liability using portion of securities received from the company at price $ 12.26 per share. | 06 Sep 2022 | 1,851 | 242,151 (0%) | 0% | 12.3 | 22,693 | Common Stock |
| Thane Wettig | Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 12.26 per share. | 06 Sep 2022 | 360 | 90,934 (0%) | 0% | 12.3 | 4,414 | Common Stock |
| Mark Eisner | Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 13.09 per share. | 01 Sep 2022 | 756 | 149,044 (0%) | 0% | 13.1 | 9,896 | Common Stock |
| Enrique A. Conterno | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 12.40 per share. | 06 Jul 2022 | 1,296 | 302,631 (0%) | 0% | 12.4 | 16,070 | Common Stock |
| Thane Wettig | Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 11.42 per share. | 22 Jun 2022 | 655 | 91,294 (0%) | 0% | 11.4 | 7,480 | Common Stock |
| James A. Schoeneck | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2022 | 15,777 | 20,477 (0%) | 0% | 0 | Common Stock | |
| James A. Schoeneck | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2022 | 25,684 | 25,684 | - | - | Stock Option (Right to Buy) | |
| Jeffrey L. Edwards | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2022 | 15,777 | 33,577 (0%) | 0% | 0 | Common Stock | |
| Jeffrey L. Edwards | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2022 | 25,684 | 25,684 | - | - | Stock Option (Right to Buy) | |
| Jeffrey W. Henderson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2022 | 25,684 | 25,684 | - | - | Stock Option (Right to Buy) | |
| Jeffrey W. Henderson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2022 | 15,777 | 33,577 (0%) | 0% | 0 | Common Stock | |
| Maykin Ho | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2022 | 25,684 | 25,684 | - | - | Stock Option (Right to Buy) | |
| Maykin Ho | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2022 | 15,777 | 31,732 (0%) | 0% | 0 | Common Stock | |
| Aoife M. Brennan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2022 | 25,684 | 25,684 | - | - | Stock Option (Right to Buy) | |
| Aoife M. Brennan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2022 | 15,777 | 24,391 (0%) | 0% | 0 | Common Stock | |
| Gerald Lema | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2022 | 15,777 | 20,477 (0%) | 0% | 0 | Common Stock | |
| Gerald Lema | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2022 | 25,684 | 25,684 | - | - | Stock Option (Right to Buy) | |
| Suzanne Blaug | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2022 | 25,684 | 25,684 | - | - | Stock Option (Right to Buy) | |
| Suzanne Blaug | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2022 | 15,777 | 29,825 (0%) | 0% | 0 | Common Stock | |
| Benjamin Cravatt | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2022 | 15,777 | 24,391 (0%) | 0% | 0 | Common Stock | |
| Benjamin Cravatt | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2022 | 25,684 | 25,684 | - | - | Stock Option (Right to Buy) | |
| Enrique A. Conterno | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 9.50 per share. | 06 Jun 2022 | 1,772 | 301,940 (0%) | 0% | 9.5 | 16,834 | Common Stock |
| Christine Chung | SVP, China Operations | Payment of exercise price or tax liability using portion of securities received from the company at price $ 9.50 per share. | 06 Jun 2022 | 1,850 | 244,002 (0%) | 0% | 9.5 | 17,575 | Common Stock |
| Thane Wettig | Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 9.50 per share. | 06 Jun 2022 | 360 | 89,961 (0%) | 0% | 9.5 | 3,420 | Common Stock |
| Mark Eisner | Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 9.61 per share. | 01 Jun 2022 | 1,141 | 149,800 (0%) | 0% | 9.6 | 10,965 | Common Stock |
| Enrique A. Conterno | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 12.73 per share. | 06 Apr 2022 | 1,311 | 303,712 (0%) | 0% | 12.7 | 16,689 | Common Stock |
| Thane Wettig | Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 13.31 per share. | 22 Mar 2022 | 655 | 90,321 (0%) | 0% | 13.3 | 8,718 | Common Stock |
| Enrique A. Conterno | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 12.69 per share. | 07 Mar 2022 | 7,081 | 305,023 (0%) | 0% | 12.7 | 89,858 | Common Stock |
| Christine Chung | SVP, China Operations | Payment of exercise price or tax liability using portion of securities received from the company at price $ 12.69 per share. | 07 Mar 2022 | 3,905 | 250,534 (0%) | 0% | 12.7 | 49,554 | Common Stock |
| Thane Wettig | Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 12.69 per share. | 07 Mar 2022 | 1,706 | 90,976 (0%) | 0% | 12.7 | 21,649 | Common Stock |
| Mark Eisner | Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 13.62 per share. | 01 Mar 2022 | 756 | 157,383 (0%) | 0% | 13.6 | 10,297 | Common Stock |
| Enrique A. Conterno | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2022 | 179,400 | 312,104 (0%) | 0% | 0 | Common Stock | |
| Enrique A. Conterno | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2022 | 298,000 | 298,000 | - | - | Stock Option (Right to Buy) | |
| Christine Chung | SVP, China Operations | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2022 | 75,000 | 75,000 | - | - | Stock Option (Right to Buy) | |
| Christine Chung | SVP, China Operations | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2022 | 45,000 | 254,439 (0%) | 0% | 0 | Common Stock | |
| Thane Wettig | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2022 | 45,000 | 92,682 (0%) | 0% | 0 | Common Stock | |
| Thane Wettig | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2022 | 75,000 | 75,000 | - | - | Stock Option (Right to Buy) | |
| Mark Eisner | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2022 | 100,000 | 100,000 | - | - | Stock Option (Right to Buy) | |
| Mark Eisner | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2022 | 60,000 | 158,139 (0%) | 0% | 0 | Common Stock | |
| Juan Graham | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2022 | 22,500 | 58,900 (0%) | 0% | 0 | Common Stock | |
| Juan Graham | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2022 | 37,500 | 37,500 | - | - | Stock Option (Right to Buy) | |
| Enrique A. Conterno | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 13.93 per share. | 06 Jan 2022 | 1,536 | 132,704 (0%) | 0% | 13.9 | 21,396 | Common Stock |
| Christine Chung | SVP, China Operations | Payment of exercise price or tax liability using portion of securities received from the company at price $ 14.82 per share. | 03 Jan 2022 | 5,284 | 209,439 (0%) | 0% | 14.8 | 78,309 | Common Stock |
| Mark Eisner | Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 14.82 per share. | 03 Jan 2022 | 7,043 | 98,139 (0%) | 0% | 14.8 | 104,377 | Common Stock |
| Thane Wettig | Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 14.97 per share. | 22 Dec 2021 | 517 | 47,682 (0%) | 0% | 15.0 | 7,739 | Common Stock |
| Christine Chung | SVP, China Operations | Payment of exercise price or tax liability using portion of securities received from the company at price $ 14.19 per share. | 06 Dec 2021 | 2,668 | 214,723 (0%) | 0% | 14.2 | 37,859 | Common Stock |
| Mark Eisner | Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 12.65 per share. | 01 Dec 2021 | 4,338 | 105,182 (0%) | 0% | 12.7 | 54,876 | Common Stock |
| Enrique A. Conterno | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 10.20 per share. | 06 Oct 2021 | 1,859 | 134,239 (0%) | 0% | 10.2 | 18,962 | Common Stock |
| Christine Chung | SVP, China Operations | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Oct 2021 | 54,170 | 217,391 (0%) | 0% | 0 | Common Stock | |
| Christine Chung | SVP, China Operations | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Oct 2021 | 32,360 | 32,360 | - | - | Stock Option (Right to Buy) | |
| Mark Eisner | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Oct 2021 | 74,520 | 109,520 (0%) | 0% | 0 | Common Stock | |
| Mark Eisner | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Oct 2021 | 44,520 | 44,520 | - | - | Stock Option (Right to Buy) | |
| Thane Wettig | Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 10.18 per share. | 22 Sep 2021 | 620 | 48,196 (0%) | 0% | 10.2 | 6,312 | Common Stock |
| Thomas F. Kearns | Director | Sale of securities on an exchange or to another person at price $ 11.58 per share. | 15 Sep 2021 | 13,100 | 39,764 (0%) | 0% | 11.6 | 151,707 | Common Stock |
| Pat Cotroneo | Executive Advisor & Former CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 12.41 per share. | 07 Sep 2021 | 2,141 | 274,536 (0%) | 0% | 12.4 | 26,570 | Common Stock |
| Christine Chung | SVP, China Operations | Payment of exercise price or tax liability using portion of securities received from the company at price $ 12.41 per share. | 07 Sep 2021 | 2,030 | 165,251 (0%) | 0% | 12.4 | 25,192 | Common Stock |
| Juan Graham | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Sep 2021 | 196,000 | 196,000 | - | - | Stock Option (Right to Buy) | |
| Juan Graham | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Sep 2021 | 35,000 | 36,400 (0%) | 0% | 0 | Common Stock | |
| Thane Wettig | Chief Commercial Officer | Purchase of securities on an exchange or from another person at price $ 11.53 per share. | 26 Aug 2021 | 3,100 | 48,816 (0%) | 0% | 11.5 | 35,743 | Common Stock |
| Enrique A. Conterno | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 25.06 per share. | 06 Jul 2021 | 1,859 | 136,098 (0%) | 0% | 25.1 | 46,587 | Common Stock |
| Thane Wettig | Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 27.65 per share. | 22 Jun 2021 | 2,593 | 45,716 (0%) | 0% | 27.6 | 71,696 | Common Stock |
| Pat Cotroneo | SVP, Finance and CFO | Sale of securities on an exchange or to another person at price $ 25.62 per share. | 15 Jun 2021 | 4,053 | 276,677 (0%) | 0% | 25.6 | 103,838 | Common Stock |
| Pat Cotroneo | SVP, Finance and CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 22.90 per share. | 07 Jun 2021 | 2,141 | 280,730 (0%) | 0% | 22.9 | 49,029 | Common Stock |
| Christine Chung | SVP, China Operations | Payment of exercise price or tax liability using portion of securities received from the company at price $ 22.90 per share. | 07 Jun 2021 | 2,030 | 165,251 (0%) | 0% | 22.9 | 46,487 | Common Stock |
| James A. Schoeneck | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 May 2021 | 7,800 | 7,800 | - | - | Stock Option (Right to Buy) | |
| James A. Schoeneck | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 May 2021 | 4,700 | 14,100 (0%) | 0% | 0 | Common Stock | |
| Thomas F. Kearns | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 May 2021 | 7,800 | 7,800 | - | - | Stock Option (Right to Buy) | |
| Thomas F. Kearns | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 May 2021 | 4,700 | 52,864 (0%) | 0% | 0 | Common Stock | |
| Jeffrey L. Edwards | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 May 2021 | 7,800 | 7,800 | - | - | Stock Option (Right to Buy) | |
| Jeffrey L. Edwards | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 May 2021 | 4,700 | 17,800 (0%) | 0% | 0 | Common Stock | |
| Jeffrey W. Henderson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 May 2021 | 4,700 | 17,800 (0%) | 0% | 0 | Common Stock | |
| Jeffrey W. Henderson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 May 2021 | 7,800 | 7,800 | - | - | Stock Option (Right to Buy) | |
| Rory B. Riggs | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 May 2021 | 7,800 | 7,800 | - | - | Stock Option (Right to Buy) | |
| Rory B. Riggs | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 May 2021 | 4,700 | 395,750 (0%) | 0% | 0 | Common Stock | |
| Kalevi Kurkijarvi | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 May 2021 | 4,700 | 37,800 (0%) | 0% | 0 | Common Stock | |
| Kalevi Kurkijarvi | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 May 2021 | 7,800 | 7,800 | - | - | Stock Option (Right to Buy) | |
| Maykin Ho | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 May 2021 | 7,800 | 7,800 | - | - | Stock Option (Right to Buy) | |
| Maykin Ho | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 May 2021 | 4,700 | 15,955 (0%) | 0% | 0 | Common Stock | |
| Aoife M. Brennan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 May 2021 | 4,700 | 8,614 (0%) | 0% | 0 | Common Stock | |
| Aoife M. Brennan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 May 2021 | 7,800 | 7,800 | - | - | Stock Option (Right to Buy) | |
| Gerald Lema | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 May 2021 | 7,800 | 7,800 | - | - | Stock Option (Right to Buy) | |
| Gerald Lema | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 May 2021 | 4,700 | 9,400 (0%) | 0% | 0 | Common Stock | |
| Suzanne Blaug | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 May 2021 | 4,700 | 14,048 (0%) | 0% | 0 | Common Stock | |
| Suzanne Blaug | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 May 2021 | 7,800 | 7,800 | - | - | Stock Option (Right to Buy) | |
| Benjamin Cravatt | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 May 2021 | 7,800 | 7,800 | - | - | Stock Option (Right to Buy) | |
| Benjamin Cravatt | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 May 2021 | 4,700 | 8,614 (0%) | 0% | 0 | Common Stock | |
| Thomas F. Kearns | Director | Sale of securities on an exchange or to another person at price $ 35.02 per share. | 11 Mar 2021 | 18,000 | 148,164 (0%) | 0% | 35.0 | 630,360 | Common Stock |
| Thomas F. Kearns | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Mar 2021 | 12,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Thomas F. Kearns | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Mar 2021 | 6,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Thomas F. Kearns | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.50 per share. | 11 Mar 2021 | 18,000 | 166,164 (0%) | 0% | 3.5 | 63,000 | Common Stock |
| Pat Cotroneo | SVP, Finance and CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 33.37 per share. | 08 Mar 2021 | 5,657 | 282,187 (0%) | 0% | 33.4 | 188,774 | Common Stock |
| Christine Chung | SVP, China Operations | Payment of exercise price or tax liability using portion of securities received from the company at price $ 33.37 per share. | 08 Mar 2021 | 5,679 | 166,597 (0%) | 0% | 33.4 | 189,508 | Common Stock |
| Elias Kouchakji | SVP, Clinical Dev, Drug Safety | Payment of exercise price or tax liability using portion of securities received from the company at price $ 33.37 per share. | 08 Mar 2021 | 5,221 | 147,346 (0%) | 0% | 33.4 | 174,225 | Common Stock |
| Enrique A. Conterno | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Feb 2021 | 164,000 | 164,000 | - | - | Stock Option (Right to Buy) | |
| Enrique A. Conterno | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Feb 2021 | 82,000 | 137,273 (0%) | 0% | 0 | Common Stock | |
| Pat Cotroneo | SVP, Finance and CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Feb 2021 | 21,700 | 287,844 (0%) | 0% | 0 | Common Stock | |
| Pat Cotroneo | SVP, Finance and CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Feb 2021 | 41,700 | 41,700 | - | - | Stock Option (Right to Buy) | |
| Christine Chung | SVP, China Operations | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Feb 2021 | 41,700 | 41,700 | - | - | Stock Option (Right to Buy) | |
| Christine Chung | SVP, China Operations | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Feb 2021 | 21,700 | 172,276 (0%) | 0% | 0 | Common Stock | |
| Elias Kouchakji | SVP, Clinical Dev, Drug Safety | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Feb 2021 | 39,900 | 39,900 | - | - | Stock Option (Right to Buy) | |
| Elias Kouchakji | SVP, Clinical Dev, Drug Safety | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Feb 2021 | 20,800 | 152,567 (0%) | 0% | 0 | Common Stock | |
| Thane Wettig | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Feb 2021 | 16,500 | 47,150 (0%) | 0% | 0 | Common Stock | |
| Thane Wettig | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Feb 2021 | 32,100 | 32,100 | - | - | Stock Option (Right to Buy) | |
| Kalevi Kurkijarvi | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Feb 2021 | 6,000 | 6,000 | - | - | Stock Option (Right to Buy) | |
| Kalevi Kurkijarvi | Director | Sale of securities on an exchange or to another person at price $ 52.93 per share. | 17 Feb 2021 | 844 | 33,100 (0%) | 0% | 52.9 | 44,673 | Common Stock |
| Kalevi Kurkijarvi | Director | Sale of securities on an exchange or to another person at price $ 52.31 per share. | 17 Feb 2021 | 5,156 | 33,944 (0%) | 0% | 52.3 | 269,710 | Common Stock |
| Kalevi Kurkijarvi | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 28.65 per share. | 17 Feb 2021 | 6,000 | 39,100 (0%) | 0% | 28.7 | 171,900 | Common Stock |
| Kalevi Kurkijarvi | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 19.05 per share. | 19 Jan 2021 | 6,000 | 39,100 (0%) | 0% | 19.1 | 114,300 | Common Stock |
| Kalevi Kurkijarvi | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Jan 2021 | 6,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Kalevi Kurkijarvi | Director | Sale of securities on an exchange or to another person at price $ 43.38 per share. | 19 Jan 2021 | 6,000 | 33,100 (0%) | 0% | 43.4 | 260,280 | Common Stock |
| Kalevi Kurkijarvi | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Jan 2021 | 5,999 | 6,000 | - | - | Stock Option (Right to Buy) | |
| Kalevi Kurkijarvi | Director | Sale of securities on an exchange or to another person at price $ 40.04 per share. | 14 Jan 2021 | 5,999 | 33,100 (0%) | 0% | 40.0 | 240,200 | Common Stock |
| Kalevi Kurkijarvi | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 19.05 per share. | 14 Jan 2021 | 5,999 | 39,099 (0%) | 0% | 19.1 | 114,281 | Common Stock |
| Enrique A. Conterno | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 38.31 per share. | 06 Jan 2021 | 5,411 | 55,273 (0%) | 0% | 38.3 | 207,295 | Common Stock |
| James A. Schoeneck | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Jan 2021 | 6,000 | 0 | - | - | Stock Option (Right to Buy) | |
| James A. Schoeneck | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 9.78 per share. | 04 Jan 2021 | 6,000 | 15,400 (0%) | 0% | 9.8 | 58,650 | Common Stock |
| Kalevi Kurkijarvi | Director | Sale of securities on an exchange or to another person at price $ 41.14 per share. | 28 Dec 2020 | 100 | 33,100 (0%) | 0% | 41.1 | 4,114 | Common Stock |
| Kalevi Kurkijarvi | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Dec 2020 | 1 | 11,999 | - | - | Stock Option (Right to Buy) | |
| Kalevi Kurkijarvi | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Dec 2020 | 6,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Kalevi Kurkijarvi | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 18.34 per share. | 28 Dec 2020 | 6,000 | 39,100 (0%) | 0% | 18.3 | 110,040 | Common Stock |
| Kalevi Kurkijarvi | Director | Sale of securities on an exchange or to another person at price $ 40.39 per share. | 28 Dec 2020 | 5,901 | 33,200 (0%) | 0% | 40.4 | 238,341 | Common Stock |
| Kalevi Kurkijarvi | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 19.00 per share. | 28 Dec 2020 | 1 | 39,101 (0%) | 0% | 19 | 19 | Common Stock |
| K. Peony Yu | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 41.61 per share. | 16 Dec 2020 | 3,350 | 192,292 (0%) | 0% | 41.6 | 139,394 | Common Stock |
| Pat Cotroneo | SVP, Finance and CFO | Sale of securities on an exchange or to another person at price $ 43.60 per share. | 15 Dec 2020 | 3,068 | 266,144 (0%) | 0% | 43.6 | 133,765 | Common Stock |
| K. Peony Yu | Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 41.99 per share. | 07 Dec 2020 | 3,292 | 195,642 (0%) | 0% | 42.0 | 138,231 | Common Stock |
| Pat Cotroneo | SVP, Finance and CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 41.99 per share. | 07 Dec 2020 | 3,014 | 269,212 (0%) | 0% | 42.0 | 126,558 | Common Stock |
| Christine Chung | SVP, China Operations | Payment of exercise price or tax liability using portion of securities received from the company at price $ 41.99 per share. | 07 Dec 2020 | 3,039 | 150,576 (0%) | 0% | 42.0 | 127,608 | Common Stock |
| Elias Kouchakji | SVP, Clinical Dev, Drug Safety | Payment of exercise price or tax liability using portion of securities received from the company at price $ 41.99 per share. | 07 Dec 2020 | 2,728 | 131,767 (0%) | 0% | 42.0 | 114,549 | Common Stock |
| Mark Eisner | Incoming Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Dec 2020 | 35,000 | 35,000 (0%) | 0% | 0 | Common Stock | |
| Mark Eisner | Incoming Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Dec 2020 | 80,000 | 80,000 | - | - | Stock Option (Right to Buy) | |
| Elias Kouchakji | SVP, Clinical Dev, Drug Safety | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Nov 2020 | 7,082 | 0 | - | - | Stock Option (Right to Buy) | |
| Elias Kouchakji | SVP, Clinical Dev, Drug Safety | Exercise or conversion of derivative security received from the company (such as an option) at price $ 14.57 per share. | 17 Nov 2020 | 7,082 | 134,495 (0%) | 0% | 14.6 | 103,220 | Common Stock |
| K. Peony Yu | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 44.01 per share. | 16 Sep 2020 | 3,351 | 198,934 (0%) | 0% | 44.0 | 147,478 | Common Stock |
| Pat Cotroneo | SVP, Finance and CFO | Sale of securities on an exchange or to another person at price $ 43.63 per share. | 15 Sep 2020 | 3,070 | 272,226 (0%) | 0% | 43.6 | 133,944 | Common Stock |
| K. Peony Yu | Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 42.16 per share. | 08 Sep 2020 | 3,291 | 202,285 (0%) | 0% | 42.2 | 138,749 | Common Stock |
| Pat Cotroneo | SVP, Finance and CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 42.16 per share. | 08 Sep 2020 | 3,014 | 275,296 (0%) | 0% | 42.2 | 127,070 | Common Stock |
| Christine Chung | SVP, China Operations | Payment of exercise price or tax liability using portion of securities received from the company at price $ 42.16 per share. | 08 Sep 2020 | 3,038 | 153,615 (0%) | 0% | 42.2 | 128,082 | Common Stock |
| Elias Kouchakji | SVP, Clinical Dev, Drug Safety | Payment of exercise price or tax liability using portion of securities received from the company at price $ 42.16 per share. | 08 Sep 2020 | 2,728 | 127,413 (0%) | 0% | 42.2 | 115,012 | Common Stock |
| K. Peony Yu | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 50.89 per share. | 03 Sep 2020 | 10,000 | 205,576 (0%) | 0% | 50.9 | 508,900 | Common Stock |
| K. Peony Yu | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Sep 2020 | 10,000 | 42,500 | - | - | Stock Option (Right to Buy) | |
| K. Peony Yu | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 18.00 per share. | 03 Sep 2020 | 10,000 | 215,576 (0%) | 0% | 18 | 180,000 | Common Stock |
| Pat Cotroneo | SVP, Finance and CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Sep 2020 | 637 | 4,618 | - | - | Stock Option (Right to Buy) | |
| Pat Cotroneo | SVP, Finance and CFO | Sale of securities on an exchange or to another person at price $ 50.91 per share. | 03 Sep 2020 | 15,004 | 278,310 (0%) | 0% | 50.9 | 763,854 | Common Stock |
| Pat Cotroneo | SVP, Finance and CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 25.40 per share. | 03 Sep 2020 | 8,671 | 293,314 (0%) | 0% | 25.4 | 220,243 | Common Stock |
| Pat Cotroneo | SVP, Finance and CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 19.39 per share. | 03 Sep 2020 | 5,696 | 284,643 (0%) | 0% | 19.4 | 110,445 | Common Stock |
| Pat Cotroneo | SVP, Finance and CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 29.66 per share. | 03 Sep 2020 | 637 | 278,947 (0%) | 0% | 29.7 | 18,893 | Common Stock |
| Pat Cotroneo | SVP, Finance and CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Sep 2020 | 8,671 | 41,579 | - | - | Stock Option (Right to Buy) | |
| Pat Cotroneo | SVP, Finance and CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Sep 2020 | 5,696 | 0 | - | - | Stock Option (Right to Buy) | |
| James A. Schoeneck | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Aug 2020 | 6,000 | 0 | - | - | Stock Option (Right to Buy) | |
| James A. Schoeneck | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.95 per share. | 20 Aug 2020 | 6,000 | 15,400 (0%) | 0% | 6.0 | 35,700 | Common Stock |
| Pat Cotroneo | SVP, Finance and CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 19.39 per share. | 07 Aug 2020 | 3,750 | 274,810 (0%) | 0% | 19.4 | 72,713 | Common Stock |
| Pat Cotroneo | SVP, Finance and CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Aug 2020 | 3,500 | 0 | - | - | Stock Option (Right to Buy) | |
| Pat Cotroneo | SVP, Finance and CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Aug 2020 | 3,750 | 5,696 | - | - | Stock Option (Right to Buy) | |
| Pat Cotroneo | SVP, Finance and CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Aug 2020 | 22,554 | 9,446 | - | - | Stock Option (Right to Buy) | |
| Pat Cotroneo | SVP, Finance and CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 18.00 per share. | 07 Aug 2020 | 3,500 | 278,310 (0%) | 0% | 18 | 63,000 | Common Stock |
| Pat Cotroneo | SVP, Finance and CFO | Sale of securities on an exchange or to another person at price $ 48.00 per share. | 07 Aug 2020 | 22,554 | 271,060 (0%) | 0% | 48 | 1,082,592 | Common Stock |
| Pat Cotroneo | SVP, Finance and CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 19.39 per share. | 07 Aug 2020 | 22,554 | 293,614 (0%) | 0% | 19.4 | 437,322 | Common Stock |
| Aoife M. Brennan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Aug 2020 | 10,400 | 10,400 | - | - | Stock Option (Right to Buy) | |
| Aoife M. Brennan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Aug 2020 | 6,496 | 6,496 | - | - | Stock Option (Right to Buy) | |
| Aoife M. Brennan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Aug 2020 | 3,914 | 3,914 (0%) | 0% | 0 | Common Stock | |
| Benjamin Cravatt | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Aug 2020 | 10,400 | 10,400 | - | - | Stock Option (Right to Buy) | |
| Benjamin Cravatt | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Aug 2020 | 6,496 | 6,496 | - | - | Stock Option (Right to Buy) | |
| Benjamin Cravatt | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Aug 2020 | 3,914 | 3,914 (0%) | 0% | 0 | Common Stock | |
| K. Peony Yu | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 42.35 per share. | 24 Jul 2020 | 3,351 | 205,576 (0%) | 0% | 42.4 | 141,915 | Common Stock |
| Thane Wettig | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jun 2020 | 90,000 | 90,000 | - | - | Stock Option (Right to Buy) | |
| Thane Wettig | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jun 2020 | 30,000 | 30,600 (0%) | 0% | 0 | Common Stock | |
| Pat Cotroneo | SVP, Finance and CFO | Sale of securities on an exchange or to another person at price $ 39.68 per share. | 16 Jun 2020 | 3,928 | 271,060 (0%) | 0% | 39.7 | 155,863 | Common Stock |
| Enrique A. Conterno | Director, Chief Executive Officer | Purchase of securities on an exchange or from another person at price $ 36.29 per share. | 10 Jun 2020 | 8,000 | 8,000 (0%) | 0% | 36.3 | 290,282 | Common Stock |
| Enrique A. Conterno | Director, Chief Executive Officer | Purchase of securities on an exchange or from another person at price $ 35.28 per share. | 10 Jun 2020 | 19,800 | 27,800 (0%) | 0% | 35.3 | 698,599 | Common Stock |
| Roberto Pedro Rosenkranz | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 28.65 per share. | 09 Jun 2020 | 12,000 | 84,100 (0%) | 0% | 28.7 | 343,800 | Common Stock |
| Roberto Pedro Rosenkranz | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Jun 2020 | 12,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Roberto Pedro Rosenkranz | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Jun 2020 | 12,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Roberto Pedro Rosenkranz | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 19.05 per share. | 09 Jun 2020 | 12,000 | 96,100 (0%) | 0% | 19.1 | 228,600 | Common Stock |
| K. Peony Yu | Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 33.61 per share. | 08 Jun 2020 | 3,292 | 208,927 (0%) | 0% | 33.6 | 110,644 | Common Stock |
| Pat Cotroneo | SVP, Finance and CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 33.61 per share. | 08 Jun 2020 | 2,156 | 274,988 (0%) | 0% | 33.6 | 72,463 | Common Stock |
| Christine Chung | SVP, China Operations | Payment of exercise price or tax liability using portion of securities received from the company at price $ 33.61 per share. | 08 Jun 2020 | 3,038 | 156,653 (0%) | 0% | 33.6 | 102,107 | Common Stock |
| Elias Kouchakji | SVP, Clinical Dev, Drug Safety | Payment of exercise price or tax liability using portion of securities received from the company at price $ 33.61 per share. | 08 Jun 2020 | 2,728 | 130,141 (0%) | 0% | 33.6 | 91,688 | Common Stock |
| James A. Schoeneck | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jun 2020 | 7,800 | 7,800 | - | - | Stock Option (Right to Buy) | |
| James A. Schoeneck | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jun 2020 | 4,700 | 9,400 (0%) | 0% | 0 | Common Stock | |
| Thomas F. Kearns | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jun 2020 | 4,700 | 148,164 (0%) | 0% | 0 | Common Stock | |
| Thomas F. Kearns | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jun 2020 | 7,800 | 7,800 | - | - | Stock Option (Right to Buy) | |
| Jeffrey L. Edwards | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jun 2020 | 7,800 | 7,800 | - | - | Stock Option (Right to Buy) | |
| Jeffrey L. Edwards | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jun 2020 | 4,700 | 13,100 (0%) | 0% | 0 | Common Stock | |
| Jeffrey W. Henderson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jun 2020 | 7,800 | 7,800 | - | - | Stock Option (Right to Buy) | |
| Jeffrey W. Henderson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jun 2020 | 4,700 | 13,100 (0%) | 0% | 0 | Common Stock | |
| Rory B. Riggs | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jun 2020 | 7,800 | 7,800 | - | - | Stock Option (Right to Buy) | |
| Rory B. Riggs | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jun 2020 | 4,700 | 391,050 (0%) | 0% | 0 | Common Stock | |
| Kalevi Kurkijarvi | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jun 2020 | 4,700 | 33,100 (0%) | 0% | 0 | Common Stock | |
| Kalevi Kurkijarvi | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jun 2020 | 7,800 | 7,800 | - | - | Stock Option (Right to Buy) | |
| Roberto Pedro Rosenkranz | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jun 2020 | 4,700 | 72,100 (0%) | 0% | 0 | Common Stock | |
| Roberto Pedro Rosenkranz | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jun 2020 | 7,800 | 7,800 | - | - | Stock Option (Right to Buy) | |
| Maykin Ho | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jun 2020 | 4,700 | 11,255 (0%) | 0% | 0 | Common Stock | |
| Maykin Ho | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jun 2020 | 7,800 | 7,800 | - | - | Stock Option (Right to Buy) | |
| Gerald Lema | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jun 2020 | 4,700 | 9,400 (0%) | 0% | 0 | Common Stock | |
| Gerald Lema | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jun 2020 | 7,800 | 7,800 | - | - | Stock Option (Right to Buy) | |
| Suzanne Blaug | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jun 2020 | 4,700 | 9,348 (0%) | 0% | 0 | Common Stock | |
| Suzanne Blaug | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jun 2020 | 7,800 | 7,800 | - | - | Stock Option (Right to Buy) | |
| Thomas F. Kearns | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Mar 2020 | 6,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Thomas F. Kearns | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Mar 2020 | 12,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Thomas F. Kearns | Director | Sale of securities on an exchange or to another person at price $ 23.17 per share. | 19 Mar 2020 | 18,000 | 143,464 (0%) | 0% | 23.2 | 417,074 | Common Stock |
| Thomas F. Kearns | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.90 per share. | 19 Mar 2020 | 18,000 | 161,464 (0%) | 0% | 2.9 | 52,200 | Common Stock |
| K. Peony Yu | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Mar 2020 | 75,000 | 75,000 | - | - | Stock Option (Right to Buy) | |
| K. Peony Yu | Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 39.71 per share. | 06 Mar 2020 | 9,826 | 162,791 (0%) | 0% | 39.7 | 390,190 | Common Stock |
| K. Peony Yu | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 19.39 per share. | 06 Mar 2020 | 3,750 | 166,541 (0%) | 0% | 19.4 | 72,713 | Common Stock |
| K. Peony Yu | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Mar 2020 | 45,000 | 211,541 (0%) | 0% | 0 | Common Stock | |
| K. Peony Yu | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Mar 2020 | 3,750 | 56,250 | - | - | Stock Option (Right to Buy) | |
| Pat Cotroneo | SVP, Finance and CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Mar 2020 | 40,000 | 276,466 (0%) | 0% | 0 | Common Stock | |
| Pat Cotroneo | SVP, Finance and CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 39.71 per share. | 06 Mar 2020 | 4,881 | 245,705 (0%) | 0% | 39.7 | 193,825 | Common Stock |
| Pat Cotroneo | SVP, Finance and CFO | Sale of securities on an exchange or to another person at price $ 26.36 per share. | 06 Mar 2020 | 9,239 | 236,466 (0%) | 0% | 26.4 | 243,540 | Common Stock |
| Pat Cotroneo | SVP, Finance and CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Mar 2020 | 66,250 | 66,250 | - | - | Stock Option (Right to Buy) | |
| Christine Chung | SVP, China Operations | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Mar 2020 | 400 | 42,064 | - | - | Stock Option (Right to Buy) | |
| Christine Chung | SVP, China Operations | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Mar 2020 | 7,345 | 34,719 | - | - | Stock Option (Right to Buy) | |
| Christine Chung | SVP, China Operations | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Mar 2020 | 66,250 | 66,250 | - | - | Stock Option (Right to Buy) | |
| Christine Chung | SVP, China Operations | Sale of securities on an exchange or to another person at price $ 26.08 per share. | 06 Mar 2020 | 6,215 | 159,013 (0%) | 0% | 26.1 | 162,087 | Common Stock |
| Christine Chung | SVP, China Operations | Sale of securities on an exchange or to another person at price $ 25.32 per share. | 06 Mar 2020 | 830 | 165,228 (0%) | 0% | 25.3 | 21,016 | Common Stock |
| Christine Chung | SVP, China Operations | Sale of securities on an exchange or to another person at price $ 23.93 per share. | 06 Mar 2020 | 300 | 166,058 (0%) | 0% | 23.9 | 7,179 | Common Stock |
| Christine Chung | SVP, China Operations | Exercise or conversion of derivative security received from the company (such as an option) at price $ 25.40 per share. | 06 Mar 2020 | 7,345 | 166,358 (0%) | 0% | 25.4 | 186,563 | Common Stock |
| Christine Chung | SVP, China Operations | Sale of securities on an exchange or to another person at price $ 25.68 per share. | 06 Mar 2020 | 1,500 | 159,013 (0%) | 0% | 25.7 | 38,520 | Common Stock |
| Christine Chung | SVP, China Operations | Sale of securities on an exchange or to another person at price $ 24.56 per share. | 06 Mar 2020 | 1,500 | 160,513 (0%) | 0% | 24.6 | 36,840 | Common Stock |
| Christine Chung | SVP, China Operations | Sale of securities on an exchange or to another person at price $ 23.69 per share. | 06 Mar 2020 | 905 | 162,013 (0%) | 0% | 23.7 | 21,439 | Common Stock |
| Christine Chung | SVP, China Operations | Exercise or conversion of derivative security received from the company (such as an option) at price $ 25.40 per share. | 06 Mar 2020 | 400 | 162,918 (0%) | 0% | 25.4 | 10,160 | Common Stock |
| Christine Chung | SVP, China Operations | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Mar 2020 | 40,000 | 162,518 (0%) | 0% | 0 | Common Stock | |
| Christine Chung | SVP, China Operations | Payment of exercise price or tax liability using portion of securities received from the company at price $ 39.71 per share. | 06 Mar 2020 | 10,126 | 122,518 (0%) | 0% | 39.7 | 402,103 | Common Stock |
| Elias Kouchakji | SVP, Clinical Dev, Drug Safety | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Mar 2020 | 37,500 | 132,191 (0%) | 0% | 0 | Common Stock | |
| Elias Kouchakji | SVP, Clinical Dev, Drug Safety | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Mar 2020 | 62,500 | 62,500 | - | - | Stock Option (Right to Buy) | |
| Elias Kouchakji | SVP, Clinical Dev, Drug Safety | Payment of exercise price or tax liability using portion of securities received from the company at price $ 39.71 per share. | 06 Mar 2020 | 6,525 | 94,691 (0%) | 0% | 39.7 | 259,108 | Common Stock |
| Christine Chung | SVP, China Operations | Sale of securities on an exchange or to another person at price $ 46.28 per share. | 11 Feb 2020 | 600 | 132,644 (0%) | 0% | 46.3 | 27,768 | Common Stock |
| Christine Chung | SVP, China Operations | Sale of securities on an exchange or to another person at price $ 45.94 per share. | 11 Feb 2020 | 5,025 | 133,244 (0%) | 0% | 45.9 | 230,849 | Common Stock |
| Christine Chung | SVP, China Operations | Exercise or conversion of derivative security received from the company (such as an option) at price $ 25.40 per share. | 11 Feb 2020 | 5,625 | 138,269 (0%) | 0% | 25.4 | 142,875 | Common Stock |
| Christine Chung | SVP, China Operations | Exercise or conversion of derivative security received from the company (such as an option) at price $ 25.40 per share. | 11 Feb 2020 | 5,625 | 138,269 (0%) | 0% | 25.4 | 142,875 | Common Stock |
| Christine Chung | SVP, China Operations | Sale of securities on an exchange or to another person at price $ 44.48 per share. | 11 Feb 2020 | 5,625 | 132,644 (0%) | 0% | 44.5 | 250,200 | Common Stock |
| Christine Chung | SVP, China Operations | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Feb 2020 | 5,625 | 42,464 | - | - | Stock Option (Right to Buy) | |
| Christine Chung | SVP, China Operations | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Feb 2020 | 5,625 | 48,089 | - | - | Stock Option (Right to Buy) | |
| Kalevi Kurkijarvi | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 18.34 per share. | 10 Feb 2020 | 6,000 | 34,400 (0%) | 0% | 18.3 | 110,040 | Common Stock |
| Kalevi Kurkijarvi | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Feb 2020 | 6,000 | 6,000 | - | - | Stock Option (Right to Buy) | |
| Kalevi Kurkijarvi | Director | Sale of securities on an exchange or to another person at price $ 42.69 per share. | 10 Feb 2020 | 6,000 | 28,400 (0%) | 0% | 42.7 | 256,140 | Common Stock |
| James A. Schoeneck | Director, Interim President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 43.35 per share. | 06 Jan 2020 | 10,928 | 22,422 (0%) | 0% | 43.4 | 473,729 | Common Stock |
| Enrique A. Conterno | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jan 2020 | 300,000 | 300,000 | - | - | Stock Option (Right to Buy) | |
| Enrique A. Conterno | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jan 2020 | 60,000 | 60,000 (0%) | 0% | 0 | Common Stock | |
| Kalevi Kurkijarvi | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 18.00 per share. | 06 Jan 2020 | 6,000 | 34,400 (0%) | 0% | 18 | 108,000 | Common Stock |
| Kalevi Kurkijarvi | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Jan 2020 | 6,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Kalevi Kurkijarvi | Director | Sale of securities on an exchange or to another person at price $ 42.66 per share. | 06 Jan 2020 | 6,000 | 28,400 (0%) | 0% | 42.7 | 255,960 | Common Stock |
| Christine Chung | SVP, China Operations | Exercise or conversion of derivative security received from the company (such as an option) at price $ 25.40 per share. | 06 Jan 2020 | 5,625 | 138,269 (0%) | 0% | 25.4 | 142,875 | Common Stock |
| Christine Chung | SVP, China Operations | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Jan 2020 | 5,625 | 53,714 | - | - | Stock Option (Right to Buy) | |
| Christine Chung | SVP, China Operations | Sale of securities on an exchange or to another person at price $ 42.76 per share. | 06 Jan 2020 | 5,625 | 132,644 (0%) | 0% | 42.8 | 240,525 | Common Stock |
| Christine Chung | SVP, China Operations | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Jan 2020 | 5,625 | 59,339 | - | - | Stock Option (Right to Buy) | |
| Christine Chung | SVP, China Operations | Exercise or conversion of derivative security received from the company (such as an option) at price $ 25.40 per share. | 06 Jan 2020 | 5,625 | 138,269 (0%) | 0% | 25.4 | 142,875 | Common Stock |
| Christine Chung | SVP, China Operations | Sale of securities on an exchange or to another person at price $ 42.98 per share. | 06 Jan 2020 | 5,625 | 132,644 (0%) | 0% | 43.0 | 241,763 | Common Stock |
| Pat Cotroneo | SVP, Finance and CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.50 per share. | 20 Dec 2019 | 18,000 | 271,788 (0%) | 0% | 3.5 | 63,000 | Common Stock |
| Pat Cotroneo | SVP, Finance and CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Dec 2019 | 17,254 | 0 | - | - | Stock Option (Right to Buy) | |
| Pat Cotroneo | SVP, Finance and CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Dec 2019 | 21,000 | 0 | - | - | Stock Optin (Right to Buy) | |
| Pat Cotroneo | SVP, Finance and CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Dec 2019 | 18,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Pat Cotroneo | SVP, Finance and CFO | Sale of securities on an exchange or to another person at price $ 46.27 per share. | 20 Dec 2019 | 12,729 | 250,586 (0%) | 0% | 46.3 | 588,971 | Common Stock |
| Pat Cotroneo | SVP, Finance and CFO | Sale of securities on an exchange or to another person at price $ 45.51 per share. | 20 Dec 2019 | 46,727 | 263,315 (0%) | 0% | 45.5 | 2,126,546 | Common Stock |
| Pat Cotroneo | SVP, Finance and CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 14.57 per share. | 20 Dec 2019 | 17,254 | 310,042 (0%) | 0% | 14.6 | 251,477 | Common Stock |
| Pat Cotroneo | SVP, Finance and CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.95 per share. | 20 Dec 2019 | 21,000 | 292,788 (0%) | 0% | 6.0 | 124,950 | Common Stock |
| K. Peony Yu | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 46.68 per share. | 16 Dec 2019 | 3,420 | 172,617 (0%) | 0% | 46.7 | 159,646 | Common Stock |
| Christine Chung | SVP, China Operations | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Dec 2019 | 5,625 | 64,964 | - | - | Stock Option (Right to Buy) | |
| Christine Chung | SVP, China Operations | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Dec 2019 | 2,120 | 70,589 | - | - | Stock Option (Right to Buy) | |
| Christine Chung | SVP, China Operations | Sale of securities on an exchange or to another person at price $ 47.47 per share. | 16 Dec 2019 | 289 | 132,644 (0%) | 0% | 47.5 | 13,719 | Common Stock |
| Christine Chung | SVP, China Operations | Sale of securities on an exchange or to another person at price $ 46.95 per share. | 16 Dec 2019 | 5,336 | 132,933 (0%) | 0% | 46.9 | 250,525 | Common Stock |
| Christine Chung | SVP, China Operations | Exercise or conversion of derivative security received from the company (such as an option) at price $ 25.40 per share. | 16 Dec 2019 | 5,625 | 138,269 (0%) | 0% | 25.4 | 142,875 | Common Stock |
| Christine Chung | SVP, China Operations | Sale of securities on an exchange or to another person at price $ 47.37 per share. | 16 Dec 2019 | 2,775 | 132,644 (0%) | 0% | 47.4 | 131,452 | Common Stock |
| Christine Chung | SVP, China Operations | Sale of securities on an exchange or to another person at price $ 46.80 per share. | 16 Dec 2019 | 2,850 | 135,419 (0%) | 0% | 46.8 | 133,380 | Common Stock |
| Christine Chung | SVP, China Operations | Exercise or conversion of derivative security received from the company (such as an option) at price $ 25.40 per share. | 16 Dec 2019 | 2,120 | 138,269 (0%) | 0% | 25.4 | 53,848 | Common Stock |
| Kalevi Kurkijarvi | None | Sale of securities on an exchange or to another person at price $ 47.50 per share. | 09 Dec 2019 | 6,000 | 28,400 (0%) | 0% | 47.5 | 285,000 | Common Stock |
| Kalevi Kurkijarvi | None | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Dec 2019 | 6,000 | 6,000 | - | - | Stock Option (Right to Buy) | |
| Kalevi Kurkijarvi | None | Exercise or conversion of derivative security received from the company (such as an option) at price $ 18.00 per share. | 09 Dec 2019 | 6,000 | 34,400 (0%) | 0% | 18 | 108,000 | Common Stock |
| Pat Cotroneo | SVP, Finance and CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 47.39 per share. | 06 Dec 2019 | 3,144 | 253,788 (0%) | 0% | 47.4 | 148,994 | Common Stock |
| Christine Chung | SVP, China Operations | Payment of exercise price or tax liability using portion of securities received from the company at price $ 47.39 per share. | 06 Dec 2019 | 3,479 | 136,149 (0%) | 0% | 47.4 | 164,870 | Common Stock |
| Elias Kouchakji | SVP, Clinical Dev, Drug Safety | Payment of exercise price or tax liability using portion of securities received from the company at price $ 47.39 per share. | 06 Dec 2019 | 2,442 | 101,216 (0%) | 0% | 47.4 | 115,726 | Common Stock |
| K. Peony Yu | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Dec 2019 | 657 | 0 | - | - | Stock Option (Right to Buy) | |
| K. Peony Yu | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Dec 2019 | 3,500 | 52,500 | - | - | Stock Option (Right to Buy) | |
| K. Peony Yu | Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 47.39 per share. | 04 Dec 2019 | 3,360 | 176,037 (0%) | 0% | 47.4 | 159,230 | Common Stock |
| K. Peony Yu | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 18.00 per share. | 04 Dec 2019 | 3,500 | 179,397 (0%) | 0% | 18 | 63,000 | Common Stock |
| K. Peony Yu | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 14.58 per share. | 04 Dec 2019 | 657 | 175,897 (0%) | 0% | 14.6 | 9,576 | Common Stock |
| Christine Chung | SVP, China Operations | Exercise or conversion of derivative security received from the company (such as an option) at price $ 19.39 per share. | 13 Nov 2019 | 5,625 | 145,253 (0%) | 0% | 19.4 | 109,069 | Common Stock |
| Christine Chung | SVP, China Operations | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Nov 2019 | 2,291 | 72,709 | - | - | Stock Option (Right to Buy) | |
| Christine Chung | SVP, China Operations | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Nov 2019 | 3,334 | 25,000 | - | - | Stock Option (Right to Buy) | |
| Christine Chung | SVP, China Operations | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Nov 2019 | 5,625 | 28,334 | - | - | Stock Option (Right to Buy) | |
| Christine Chung | SVP, China Operations | Sale of securities on an exchange or to another person at price $ 35.18 per share. | 13 Nov 2019 | 2,025 | 139,628 (0%) | 0% | 35.2 | 71,240 | Common Stock |
| Christine Chung | SVP, China Operations | Sale of securities on an exchange or to another person at price $ 34.50 per share. | 13 Nov 2019 | 3,600 | 141,653 (0%) | 0% | 34.5 | 124,200 | Common Stock |
| Christine Chung | SVP, China Operations | Exercise or conversion of derivative security received from the company (such as an option) at price $ 25.40 per share. | 13 Nov 2019 | 2,291 | 145,253 (0%) | 0% | 25.4 | 58,191 | Common Stock |
| Christine Chung | SVP, China Operations | Exercise or conversion of derivative security received from the company (such as an option) at price $ 19.39 per share. | 13 Nov 2019 | 3,334 | 142,962 (0%) | 0% | 19.4 | 64,646 | Common Stock |
| Christine Chung | SVP, China Operations | Sale of securities on an exchange or to another person at price $ 34.54 per share. | 13 Nov 2019 | 5,625 | 139,628 (0%) | 0% | 34.5 | 194,288 | Common Stock |
| Pat Cotroneo | SVP, Finance and CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Nov 2019 | 12,500 | 0 | - | - | Stock Option (Right to Buy) | |
| Pat Cotroneo | SVP, Finance and CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.90 per share. | 08 Nov 2019 | 12,500 | 256,932 (0%) | 0% | 2.9 | 36,250 | Common Stock |
| Kalevi Kurkijarvi | None | Sale of securities on an exchange or to another person at price $ 38.08 per share. | 07 Nov 2019 | 4,514 | 29,886 (0%) | 0% | 38.1 | 171,893 | Common Stock |
| Kalevi Kurkijarvi | None | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Nov 2019 | 6,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Kalevi Kurkijarvi | None | Sale of securities on an exchange or to another person at price $ 38.85 per share. | 07 Nov 2019 | 1,486 | 28,400 (0%) | 0% | 38.8 | 57,731 | Common Stock |
| Kalevi Kurkijarvi | None | Exercise or conversion of derivative security received from the company (such as an option) at price $ 9.78 per share. | 07 Nov 2019 | 6,000 | 34,400 (0%) | 0% | 9.8 | 58,650 | Common Stock |
| Christine Chung | SVP, China Operations | Sale of securities on an exchange or to another person at price $ 37.10 per share. | 08 Oct 2019 | 2,400 | 139,628 (0%) | 0% | 37.1 | 89,040 | Common Stock |
| Christine Chung | SVP, China Operations | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Oct 2019 | 5,625 | 33,959 | - | - | Stock Option (Right to Buy) | |
| Christine Chung | SVP, China Operations | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Oct 2019 | 5,625 | 39,584 | - | - | Stock Option (Right to Buy) | |
| Christine Chung | SVP, China Operations | Sale of securities on an exchange or to another person at price $ 36.58 per share. | 08 Oct 2019 | 5,625 | 139,628 (0%) | 0% | 36.6 | 205,763 | Common Stock |
| Christine Chung | SVP, China Operations | Exercise or conversion of derivative security received from the company (such as an option) at price $ 19.39 per share. | 08 Oct 2019 | 5,625 | 145,253 (0%) | 0% | 19.4 | 109,069 | Common Stock |
| Christine Chung | SVP, China Operations | Exercise or conversion of derivative security received from the company (such as an option) at price $ 19.39 per share. | 08 Oct 2019 | 5,625 | 145,253 (0%) | 0% | 19.4 | 109,069 | Common Stock |
| Christine Chung | SVP, China Operations | Sale of securities on an exchange or to another person at price $ 36.55 per share. | 08 Oct 2019 | 3,225 | 142,028 (0%) | 0% | 36.6 | 117,874 | Common Stock |
| Kalevi Kurkijarvi | None | Exercise or conversion of derivative security received from the company (such as an option) at price $ 9.78 per share. | 07 Oct 2019 | 6,000 | 34,400 (0%) | 0% | 9.8 | 58,650 | Common Stock |
| Kalevi Kurkijarvi | None | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Oct 2019 | 6,000 | 6,000 | - | - | Stock Option (Right to Buy) | |
| Kalevi Kurkijarvi | None | Sale of securities on an exchange or to another person at price $ 36.73 per share. | 07 Oct 2019 | 6,000 | 28,400 (0%) | 0% | 36.7 | 220,380 | Common Stock |
| Christine Chung | SVP, China Operations | Exercise or conversion of derivative security received from the company (such as an option) at price $ 19.39 per share. | 19 Sep 2019 | 2,120 | 145,253 (0%) | 0% | 19.4 | 41,107 | Common Stock |
| Christine Chung | SVP, China Operations | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Sep 2019 | 5,625 | 45,209 | - | - | Stock Option (Right to Buy) | |
| Christine Chung | SVP, China Operations | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Sep 2019 | 2,120 | 50,834 | - | - | Stock Option (Right to Buy) | |
| Christine Chung | SVP, China Operations | Sale of securities on an exchange or to another person at price $ 39.87 per share. | 19 Sep 2019 | 5,625 | 139,628 (0%) | 0% | 39.9 | 224,269 | Common Stock |
| Christine Chung | SVP, China Operations | Exercise or conversion of derivative security received from the company (such as an option) at price $ 19.39 per share. | 19 Sep 2019 | 5,625 | 145,253 (0%) | 0% | 19.4 | 109,069 | Common Stock |
| Christine Chung | SVP, China Operations | Sale of securities on an exchange or to another person at price $ 40.75 per share. | 19 Sep 2019 | 3,400 | 139,628 (0%) | 0% | 40.8 | 138,550 | Common Stock |
| Christine Chung | SVP, China Operations | Sale of securities on an exchange or to another person at price $ 40.00 per share. | 19 Sep 2019 | 2,225 | 143,028 (0%) | 0% | 40 | 89,000 | Common Stock |
| James A. Schoeneck | Director, Interim CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Sep 2019 | 97,100 | 97,100 | - | - | Stock Option (Right to Buy) | |
| James A. Schoeneck | Director, Interim CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Sep 2019 | 57,300 | 62,000 (0%) | 0% | 0 | Common Stock | |
| Pat Cotroneo | SVP, Finance and CFO | Sale of securities on an exchange or to another person at price $ 41.38 per share. | 17 Sep 2019 | 3,201 | 244,432 (0%) | 0% | 41.4 | 132,457 | Common Stock |
| K. Peony Yu | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 40.92 per share. | 16 Sep 2019 | 3,419 | 175,240 (0%) | 0% | 40.9 | 139,905 | Common Stock |
| Kalevi Kurkijarvi | None | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.95 per share. | 09 Sep 2019 | 6,000 | 34,400 (0%) | 0% | 6.0 | 35,700 | Common Stock |
| Kalevi Kurkijarvi | None | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Sep 2019 | 6,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Kalevi Kurkijarvi | None | Sale of securities on an exchange or to another person at price $ 41.67 per share. | 09 Sep 2019 | 420 | 28,400 (0%) | 0% | 41.7 | 17,501 | Common Stock |
| Kalevi Kurkijarvi | None | Sale of securities on an exchange or to another person at price $ 40.90 per share. | 09 Sep 2019 | 5,580 | 28,820 (0%) | 0% | 40.9 | 228,222 | Common Stock |
| K. Peony Yu | Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 41.68 per share. | 06 Sep 2019 | 8,317 | 178,659 (0%) | 0% | 41.7 | 346,653 | Common Stock |
| Pat Cotroneo | SVP, Finance and CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 41.68 per share. | 06 Sep 2019 | 3,144 | 247,633 (0%) | 0% | 41.7 | 131,042 | Common Stock |
| Christine Chung | SVP, China Operations | Payment of exercise price or tax liability using portion of securities received from the company at price $ 41.68 per share. | 06 Sep 2019 | 8,437 | 143,133 (0%) | 0% | 41.7 | 351,654 | Common Stock |
| Elias Kouchakji | SVP, Clinical Dev, Drug Safety | Payment of exercise price or tax liability using portion of securities received from the company at price $ 41.68 per share. | 06 Sep 2019 | 5,541 | 103,658 (0%) | 0% | 41.7 | 230,949 | Common Stock |
| Christine Chung | SVP, China Operations | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Aug 2019 | 5,625 | 52,954 | - | - | Stock Option (Right to Buy) | |
| Christine Chung | SVP, China Operations | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Aug 2019 | 5,625 | 58,579 | - | - | Stock Option (Right to Buy) | |
| Christine Chung | SVP, China Operations | Sale of securities on an exchange or to another person at price $ 43.68 per share. | 22 Aug 2019 | 584 | 151,570 (0%) | 0% | 43.7 | 25,509 | Common Stock |
| Christine Chung | SVP, China Operations | Sale of securities on an exchange or to another person at price $ 42.94 per share. | 22 Aug 2019 | 1,816 | 152,154 (0%) | 0% | 42.9 | 77,979 | Common Stock |
| Christine Chung | SVP, China Operations | Sale of securities on an exchange or to another person at price $ 42.05 per share. | 22 Aug 2019 | 3,225 | 153,970 (0%) | 0% | 42.0 | 135,611 | Common Stock |
| Christine Chung | SVP, China Operations | Exercise or conversion of derivative security received from the company (such as an option) at price $ 19.39 per share. | 22 Aug 2019 | 5,625 | 157,195 (0%) | 0% | 19.4 | 109,069 | Common Stock |
| Christine Chung | SVP, China Operations | Sale of securities on an exchange or to another person at price $ 44.67 per share. | 22 Aug 2019 | 300 | 151,570 (0%) | 0% | 44.7 | 13,401 | Common Stock |
| Christine Chung | SVP, China Operations | Sale of securities on an exchange or to another person at price $ 43.79 per share. | 22 Aug 2019 | 5,325 | 151,870 (0%) | 0% | 43.8 | 233,182 | Common Stock |
| Christine Chung | SVP, China Operations | Exercise or conversion of derivative security received from the company (such as an option) at price $ 19.39 per share. | 22 Aug 2019 | 5,625 | 157,195 (0%) | 0% | 19.4 | 109,069 | Common Stock |
| Thomas B. Neff | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 43.77 per share. | 21 Aug 2019 | 1,418 | 44,238 (0%) | 0% | 43.8 | 62,066 | Common Stock |
| Thomas B. Neff | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 44.73 per share. | 21 Aug 2019 | 1,300 | 2,326,612 (2%) | 0% | 44.7 | 58,149 | Common Stock |
| Thomas B. Neff | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 43.80 per share. | 21 Aug 2019 | 17,100 | 2,327,912 (2%) | 0% | 43.8 | 748,980 | Common Stock |
| Thomas B. Neff | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.90 per share. | 21 Aug 2019 | 6,834 | 2,345,012 (2%) | 0% | 2.9 | 19,819 | Common Stock |
| Thomas B. Neff | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 44.81 per share. | 21 Aug 2019 | 1,418 | 45,656 (0%) | 0% | 44.8 | 63,541 | Common Stock |
| Thomas B. Neff | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 44.79 per share. | 21 Aug 2019 | 18,400 | 2,338,178 (2%) | 0% | 44.8 | 824,136 | Common Stock |
| Thomas B. Neff | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.90 per share. | 21 Aug 2019 | 6,834 | 2,356,578 (2%) | 0% | 2.9 | 19,819 | Common Stock |
| Thomas B. Neff | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Aug 2019 | 6,834 | 177,702 | - | - | Stock Option (Right to Buy) | |
| Thomas B. Neff | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Aug 2019 | 6,834 | 184,536 | - | - | Stock Option (Right to Buy) | |
| Thomas B. Neff | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 45.67 per share. | 12 Aug 2019 | 300 | 48,492 (0%) | 0% | 45.7 | 13,701 | Common Stock |
| Thomas B. Neff | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 45.04 per share. | 12 Aug 2019 | 1,118 | 48,792 (0%) | 0% | 45.0 | 50,355 | Common Stock |
| Thomas B. Neff | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 44.98 per share. | 12 Aug 2019 | 10,700 | 2,369,010 (2%) | 0% | 45.0 | 481,286 | Common Stock |
| Thomas B. Neff | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 45.59 per share. | 12 Aug 2019 | 7,700 | 2,361,310 (2%) | 0% | 45.6 | 351,043 | Common Stock |